This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

XTL Biopharmaceuticals, Ltd. Completes The Acquisition Of MinoGuard

HERZELIYA, Israel, November 30, 2011 /PRNewswire/ --

MinoGuard develops drugs to treat mental health diseases. MinoGuard's lead drug for the treatment of schizophrenia patients is intended to improve the efficacy of existing treatments and minimize their side effects.

MinoGuard has successfully completed a phase 2a clinical trial conducted on about 70 schizophrenics and demonstrated that the use of the drug enhances the positive symptoms of the disease and minimizes the negative symptoms.

On November 30, 2011, XTL announced that it had completed the acquisition of MinoGuard Ltd. MinoGuard was founded in 2007 in order to develop and commercialize combination therapies for treating psychotic diseases, focusing on schizophrenia.

MinoGuard was founded by Mor Research Applications Ltd., technology transfer office of Clalit Health Services, on the basis of a discovery made by Prof. Yechiel Levkovitz and Dr. Shlomo Mendlovic, heads of departments at the Shalvata Mental Health Center.

SAM-101, MinoGuard's lead drug, is based on a combination of existing anti-psychotic drugs and a recognized medicinal compound.

Schizophrenia is a severe (psychotic) chronic mental health disorder, one of the most frequent mental health diseases. It affects most of the mental and social functioning capabilities, moods, perceptions, thoughts and cognitive functions.

MinoGuard has successfully completed a Phase 2a prospective, randomized, double-blind, placebo-controlled, clinical trial conducted on about 70 schizophrenics. The trial's endpoints were met, demonstrating that SAM-101 improves the positive symptoms of the disease as well as the patients' cognitive state, minimizes the negative symptoms (social parameters and patient cognition) and reduces weight gain side effect among patients.

Ronen Twito, XTL's CFO, stated that "the execution of the transaction by way of paying royalties on sales/sublicenses and milestone based payments throughout the clinical development process creates a business partnership with the technology developers that will allow coordinating the best business and financial efforts for future SAM-101 development."

According to estimates of the US National Institute of Mental Health, about 1.1% of the adult population in the US has schizophrenia. Decision Resources estimated the schizophrenia therapy market at some $ 6.4 billion in 2010.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs